Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M in funding at the series e stage. The team comprises 10 (Jun 30, 2026) employees. The company operates in the Oncology sector with additional focus on Genomics. Its business model centers on Diversified. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M at the Series E stage. Backed by investors including SDIC, Goldstone Investment, National Research Fund, General Technology Venture Capital, CITIC and others.
← All startups
Xiantong Pharmaceutical
Series EDeveloper of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M in funding at the series e stage. The team comprises 10 (Jun 30, 2026) employees. The company operates in…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Theranostics
Institutional investors
SDICGoldstone InvestmentNational Research FundGeneral Technology Venture CapitalCITICLangmafeng Venture CapitalDeyi CapitalCenturium CapitalSinopharm CapitalQiming Venture Partners3E Bioventures CapitalCICCEverest Ventures GroupLotus CapitalSaiying Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.
Similar startups
Raising like Xiantong Pharmaceutical?
Analyze your pitch deck before your next raise.
Analyze My Deck →